Premium
Randomized, placebo controlled and double‐blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta‐analysis
Author(s) -
Wang Hongsheng,
Zuo Dongqing,
Sun Mengxiong,
Hua Yingqi,
Cai Zhengdong
Publication year - 2014
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12245
Subject(s) - adalimumab , medicine , ankylosing spondylitis , placebo , adverse effect , basdai , meta analysis , randomized controlled trial , spondylitis , physical therapy , disease , alternative medicine , pathology , psoriatic arthritis
Adalimumab is a fully human, anti‐ TNF monoclonal antibody of proven efficacy and safety in the treatment of the signs, symptoms and functional disability of ankylosing spondylitis ( AS ). A systematic review and meta‐analysis was performed to assess the efficacy and safety of adalimumab treatment, relative to a placebo, in adult patients with AS . In the efficacy meta‐analysis, significantly more patients in the adalimumab group achieved A ssessment in AS I nternational W orking G roup ( ASAS )20 and B ath AS D isease A ctivity I ndex ( BASDAI )50 compared with patients in the placebo group. Patients in the adalimumab group also showed significant improvement in BASDAI and health‐related quality of life. With regard to adverse events, any adverse events and injection‐site reaction were significantly higher in the adalimumab group compared with the control group. This meta‐analysis shows a higher efficacy of adalimumab relative to placebo, but clinicians should be careful regarding adverse events in adalimumab‐treated patients.